Treatment of splenic marginal zone lymphoma: Should splenectomy be abandoned?

Leukemia and Lymphoma

Volumn 55, Issue 7, 2014, Pages 1463-1470

  Kalpadakis, Christina ^a   Pangalis, Gerassimos A ^b   Vassilakopoulos, Theodoros P ^c   Sachanas, Sotirios ^b   Angelopoulou, Maria K ^c  

^a UNIVERSITY OF CRETE   (Greece)

^b ATHENS MEDICAL CENTER   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Rituximab; SMZL; Splenectomy; Treatment

Indexed keywords

ALPHA INTERFERON; AZACITIDINE; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EVEROLIMUS; FLUDARABINE; LENALIDOMIDE; PENTOSTATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PURINE DERIVATIVE; RIBAVIRIN; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CYTOPENIA; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MORBIDITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; SURVIVAL TIME; SYSTEMIC DISEASE; WORLD HEALTH ORGANIZATION; LYMPHOMA, B-CELL, MARGINAL ZONE; MORTALITY; PROGNOSIS; SPLENIC NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; PROGNOSIS; SPLENECTOMY; SPLENIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84903434910     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.845884     Document Type: Review

References (58)

1. Isaacson PG, Piris MA, Berger F, et al. Splenic B-cell marginal zonelymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WorldHealth Organization classifi cation of tumours: pathology and geneticsof tumours of haematopoietic and lymphoid tissues. Lyon: IARC ; 2008.pp 185-187.
2. Matutes E, Oscier D, Montalban C, et al. Splenic marginalzonelymphoma proposals for a revision of diagnostic, staging andtherapeutic criteria. Leukemia 2008; 22: 487-495.
3. Catovsky D, Matutes E. Splenic lymphoma with circulating villouslymphocytes/splenic marginal-zone lymphoma. Semin Hematol.1999 ; 36 : 148-154.
4. Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginalzonelymphoma: a distinct clinical and pathological entity. LancetOncol 2003 ; 4 : 95-103.
5. Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginalzone lymphoma with or without villous lymphocytes. Hematologicfi ndings and outcomes in a series of 57 patients. Cancer 2004 ; 101 :2050-2057.
6. Franco V, Florena AM, Campesi G. Intrasinusoidal bone marrowinfi ltration: a possible hallmark of splenic lymphoma. Histopathology1996 ; 29 : 571-575.
7. Audouin J, Le Tourneau A, Molina T, et al. Patterns of bone marrowinvolvement in 58 patients presenting primary splenic marginalzone lymphoma with or without circulating villous lymphocytes.Br J Haematol 2003 ; 122 : 404-412.
8. Zhu D, Orchard J, Oscier DG, et al. V(H) gene analysis of splenicmarginal zone lymphomas reveals diversity in mutational status andinitiation of somatic mutation in vivo. Blood 2002; 100: 2659-2961.
9. Kalpadakis C, Pangalis G A, Dimitriadou E, et al. Mutation analysisof IgVH genes in splenic marginal zone lymphomas: correlationwith clinical characteristics and outcome. Anticancer Res 2009 ; 5 :1811-1816.
10. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenicmarginal zone lymphoma:proposal of new diagnostic and prognosticmarkers identifi ed after tissue and cDNA microarray analysis. Blood2005 ; 106 : 1831-1838.
11. Bikos V, Darzentas N, Hadzidimitriou A, et al. Over 30% ofpatients with splenic marginal zone lymphoma express the sameimmunoglobulin heavy variable gene: ontogenetic implications.Leukemia 2012; 26: 1638-1646.
12. Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginalzone lymphomas are indolent disorders at high hepatitis C virusseroprevalence with distinct presenting features but similarmorphologic and phenotypic profi les. Cancer 2004 ; 100 : 107-115.
13. Salido M, Baró C, Oscier D, et al. Cytogenetic aberrations andtheir prognostic value in a series of 330 splenic marginal zone B-celllymphomas: a multicenter study of the Splenic B-Cell LymphomaGroup. Blood 2010; 116: 1479-1488.
14. Rossi D, Trifonov V, Fangazio M, et al. The coding genomeof splenic marginal zone lymphoma: activation of NOTCH2 andother pathways regulating marginal zone development. JExp Med2012 ; 209 : 1537-1551.
15. Kiel MJ, Velusamy T, Bryan L, et al. Whole-genome sequencingidentifi es recurrent somatic NOTCH2 mutations in splenic marginalzone lymphoma. JExp Med 2012; 209: 1553-1565.
16. Traverse-Glehen A, Baseggio L, Salles G, et al. Splenic diff usered pulp small-B cell lymphoma: toward the emergence of a newlymphoma entity. Discov Med 2012; 13: 253-265.
17. Ponzoni M, Kanellis G, Pouliou E, et al. Bone marrowhistopathology in the diagnostic evaluation of splenic marginalzoneand splenic diff use red pulp small B-cell lymphoma: a reliablesubstitute for spleen histopathology? Am J Surg Pathol 2012 ; 36 :1609-1618.
18. Chacon JI, Mollejo M, Munoz E, et al. Splenic marginal zonelymphoma: clinical characteristics and prognostic factors in a series of60 patients. Blood 2002 ; 100 : 1648-1654.
19. Thieblemont C, Felman P, Berger F, et al. Treatment of splenicmarginal zone B-cell lymphoma: an analysis of 81 patients. ClinLymphoma. 2002; 3: 41-47.
20. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma withvillous lymphocytes: clinical presentation, biology and prognosticfactors in a series of 100 patients. Br J Haematol 1996 ; 93 : 731-736.
21. Parry-Jones N, Matutes E, Gruszca-Westwood AM, et al. Prognosticfeatures of splenic lymphoma with villous lymphocytes: a report on 129patients. Br J Haematol 2003 ; 120 : 759-764.
22. Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginalzone lymphoma: a prognostic model for clinical use. Blood 2006 ;107 : 4643-4649.
23. Montalban C, Arbraira V, Arcaini L, et al. Risk stratifi cationfor splenic marginal zone lymphoma based on haemoglobinconcentration, platelet count, high lactate deydrogenase level andextrahilar lymphadenopathy: development and validation on 593cases. Br J Haematol 2012; 159: 164-171.
24. Montalban C, Abraira V, Arcaini L, et al. Simplifi cation of riskstratifi cation for splenic marginal zone lymphoma: a point-based scorefor practical use. Leuk Lymphoma 2013 Jul 29. [Epub ahead of print]
25. Mulligan SP, Matutes E, Dearden C, et al. Splenic lymphoma withvillous lymphocytes: natural history and response to therapy in 50cases. Br J Haematol 1991; 78: 206-209.
26. Tsimberidou A M, Catovsky D, Schlette E, et al. Outcomes inpatients with splenic marginal zone lymphoma and marginal zonelymphoma treated with rituximab with or without chemotherapy orchemotherapy alone. Cancer 2006; 107: 125-135.
27. Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment ofsplenic marginal zone lymphoma with rituximab: progress report andcomparison with splenectomy. Oncologist 2013 ; 18 : 190-197.
28. Else M, Marin-Niebla A, de la Cruz F, et al. Rituximab, used aloneor in combination, is superior to other treatment modalities in splenicmarginal zone lymphoma. Br J Haematol 2012; 159: 322-328.
29. Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an eff ectivetreatment in patients with splenic lymphoma with villous lymphocytes.Leukemia 2000; 14: 573-575.
30. Bolam S, Orchard J, Oscier D. Fludarabine is eff ective in thetreatment of splenic lymphoma with villous lymphocytes. Br J Haematol1997 ; 99 : 158-161.
31. Iannitto E, Minardi V, Calvaruso G, et al. Deoxycoformycin(pentostatin) in the treatment of splenic marginal zone lymphoma(SMZL) with or without villous lymphocytes. Eur J Haematol2005 ; 75 : 130-135.
32. Lefrere F, Hermine O, Francois S, et al. Lack of effi cacy of2-chlorodeoxyadenoside in the treatment of splenic lymphoma withvillous lymphocytes. Leuk Lymphoma 2000; 40: 113-117.
33. Riccioni R, Caracciolo F, Galimberti S, et al. Low dose 2-CdAschedule activity in splenic marginal zone lymphomas. Hematol Oncol2003 ; 21 : 163-168.
34. Bennett M, Sharma K, Yegena S, et al. Rituximab monotherapy forsplenic marginal zone lymphoma. Haematologica 2005; 90: 856-858.
35. Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximabmonotherapy is highly eff ective in splenic marginal zone lymphoma.Hematol Oncol 2007 ; 25 : 127-131.
36. Kalpadakis C, Pangalis GA, Vassilakopoulos TP, et al. Rituximabmonotherapy is the treatment of choice for splenic marginal zonelymphoma (SMZL). Ann Oncol 2008; 19(Suppl.): Abstract 367.
37. Fabbri A, Gozzetti A, Lazzi S, et al. Activity of rituximabmonotherapy in refractory splenic marginal zone lymphomacomplicated with autoimmune hemolytic anemia. Clin LymphomaMyeloma 2006 ; 6 : 496-499.
38. Paydas S, Yavuz S, Disel U, et al. Successful rituximab therapyfor hemolytic anemia associated with relapsed splenic marginal zonelymphoma with leukemic phase. Leuk Lymphoma 2003; 44: 2165-2166.
39. Arcaini L, Orlandi E, Scotti M, et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologicremission of splenic marginal zone lymphoma. Clin Lymphoma2004 ; 4 : 250-252.
40. Brown JR, Friedberg JW, Feng Y, et al. Aphase 2 study ofconcurrent fl udarabine and rituximab for the treatment of marginalzone lymphomas. Br J Haematol 2009; 145: 741-748.
41. Cervetti G, Galimberti S, Sordi E, et al. Signifi cant effi cacy of2-chlorodeoxyadenosine rituximab in the treatment of splenicmarginal zone lymphoma (SMZL). Ann Oncol 2010; 21: 851-854.
42. Cervetti G, Galimberti S, Pelosini M, et al. Signifi cant effi cacy of2-chlorodeoxyadenosine rituximab in the treatment of splenicmarginal zone lymphoma (SMZL): extended follow-up. Ann Oncol2013 ; 24 : 2434-2438.
43. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of spleniclymphoma with villous lymphocytes after treatment of hepatitis C virusinfection. NEngl J Med 2002; 347: 89-94.
44. El Weshi A, Ribrag V, Girinski T, et al. Low and medium dosespleen radiation therapy are able to induce long-term responses insplenic lymphoma with villous lymphocytes. Br J Haematol 1998 ; 103 :1212-1213.
45. Franco V, Florena AM, Stella M, et al. Splenectomy infl uencesbone marrow infi ltration in patients with splenic marginal zone celllymphoma with or without villous lymphocytes. Cancer 2001 ; 91 :294-301.
46. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustineplus rituximab versus CHOP plus rituximab as fi rst-line treatmentfor patients with indolent and mantle-cell lymphomas: an openlabel, multicentre, randomised, phase 3 non-inferiority trial. Lancet2013 ; 381 : 1203-1210.
47. Dutia M, Deroock I, Reed-Pease C, et al. Lenalidomide overcomesFc RIIIa-mediated resistance to rituximab in patients with relapsed/refractory indolent non-Hodgkin ' s lymphoma (NHL): a correlativeanalysis of a phase 2 study. Blood 2010 ; 116(Suppl. 1) : Abstract 3967.
48. Samaniego F, Hagemeister F, McLaughlin P, et al. High responserates with lenalidomide plus rituximab for untreated indolent B-cellnon-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol 2011; 29(Suppl.): Abstract 8030.
49. Kahl B, Byrd J, Flinn I, et al. Clinical safety and activity in a phase 1study of Cal-101, an isoform-selective inhibitor of phosphatidylinositol3- kinase P110 , in patients with relapsed or refractory non-Hodgkinlymphoma. Blood 2010; 116(Suppl. 1): Abstract 1777.
50. Spurgeon S, Okada C, Huang J, et al. Targeting the epigenome:a phase I/II study of vorinostat (SAHA), cladribine (2-CdA), andrituximab in relapsed B-cell malignancies. J Clin Oncol 2010 ; 28(15Suppl.): Abstract TPS301.
51. Neiman RS, Sullivan AL, Jaffe R. Malignant lymphoma simulatingleukemic reticuloendotheliosis: a clinicopathologic study of ten cases.Cancer 1979 ; 43 : 329-342.
52. Palutke M, Tabaczka P, Mirchandani I, et al. Lymphocyticlymphoma simulating hairy cell leukemia: a consideration of reliableand unreliable diagnostic features. Cancer 1981; 48: 2047-2055.
53. Melo JV, Robinson DS, Gregory C, et al. Splenic B cell lymphomawith " villous " lymphocytes in the peripheral blood: a disorder distinctfrom hairy cell leukemia. Leukemia 1987; 1: 294-298.
54. Melo JV, Hegde U, Parreira A, et al. Splenic B cell lymphomawith circulating villous lymphocytes: diff erential diagnosis of B cellleukaemias with large spleens. J Clin Pathol 1987 ; 40 : 642-651.
55. Isaacson PG, Matutes E, Burke M, et al. The histopathologyof splenic lymphoma with villous lymphocytes. Blood 1994 1;84 :3828-3834.
56. Boussiotis VA, Kittas C, Pangalis GA. Splenic lymphoma withvillous lymphocytes: a distinct entity to be diff erentiated from hairy cellleukemia. Iatriki 1991; 60: 469-476.
57. Salles G, Seymour JF, Offner F, et al. Rituximab maintenancefor 2 years in patients with high tumour burden follicular lymphomaresponding to rituximab plus chemotherapy (PRIMA): a phase III, randomised controlled trial. Lancet 2011 ; 377 : 42-51.
58. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatmentof older patients with mantle-cell lymphoma. NEngl J Med 2012 ;367 : 520-531.